Mortality from COVID-19 in patients with tuberculosis: systematic review and meta-analysis
I. B. Lebedeva, М. A. Shmakova, О. М. Дроздова, Е. Б. Брусина
Fundamental and Clinical Medicine · 2022-03
Abstract
Aim. To perform a systematic analysis of COVID-19 adverse outcomes in patients with tuberculosis. Materials and Methods. We queried PubMed, Cochrane Library, Embase, ClinicalTrials.gov, medRxiv, bioRxiv, and Elibrary databases for studies on COVID-19-related mortality in patients with tuberculosis published from 2020 to 2022. We considered open randomised controlled trials, cohort, and case-control studies. Pseudorandomisation and interventional studies have been excluded from the analysis as well as those without a clear comparison group (i.e., patients without tuberculosis) and duplicate studies. Results. Out of 23,296 hits, 10 studies were included in our review. The risk of death in patients with COVID-19 and tuberculosis was significantly higher (odds ratio = 2.24, 95% confidence interval = 1.46 – 3.43] as compared with the patients without tuberculosis. Conclusion. Tuberculosis is associated with COVID-19-related mortality.
MeSH terms
- Medicine
- Tuberculosis
- Cochrane Library
- Meta-analysis
- Odds ratio
- Internal medicine
- Confidence interval
- Coronavirus disease 2019 (COVID-19)
- Cohort study
- Adverse effect
- MEDLINE